Tresiba FlexTouch 100 units/ml: Ultra-Long-Acting Insulin Degludec
Tresiba FlexTouch is a modern, ultra-long-acting basal insulin (insulin degludec) used to manage blood sugar levels in adults and children (from age 1) with diabetes mellitus. Manufactured by Novo Nordisk, this insulin pen is designed to provide a flat and stable glucose-lowering effect that lasts for more than 42 hours.
How Tresiba FlexTouch Works
The active ingredient, insulin degludec, forms a depot under the skin after injection. This allows for a slow and continuous release of insulin into the bloodstream. Because it lasts so long, Tresiba offers more dosing flexibility than traditional basal insulins. If you miss a dose, you can take it when you remember, provided there are at least 8 hours between injections.
Key Benefits for Diabetes Management
- Stable Blood Sugar: Reduces the risk of "highs" and "lows" (hypoglycemia) due to its steady release profile.
- Dosing Flexibility: Can be taken at any time of the day, though it is best to stick to a regular schedule.
- Easy-to-Use Pen: The FlexTouch pen has a smooth injection mechanism and does not require the push-button to extend, making it easier for those with limited hand strength.
Dosage and Administration
Tresiba is for subcutaneous injection only. It should be injected into the thigh, upper arm, or abdomen. Always rotate your injection sites to reduce the risk of skin changes (lipodystrophy). Use a new NovoFine or NovoTwist needle for every injection to ensure accuracy and prevent infection.
Safety Information
The most common side effect is hypoglycemia (low blood sugar). Always carry a fast-acting sugar source like glucose tablets or honey. If you experience severe reactions or persistent redness at the injection site, contact your healthcare provider.
For personalized advice on managing your insulin regimen, you can speak with a GoMed pharmacist online.